ReviewMedicina oral, patologia oral y cirugia bucal2019
Therapeutic tools for oral candidiasis: Current and new antifungal drugs.
Review in Medicina oral, patologia oral y cirugia bucal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 4 syntheses or guidelines pooled it, 176 citations in OpenAlex.
- Efficacy of botanical antifungal and conventional antifungal in the treatment of oral candidiasis: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Drug-resistant oral candidiasis in patients with HIV infection: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Pooled it
- Resistance profiles to antifungal agents in Candida albicans isolated from human oral cavities: systematic review and meta-analysis.Clinical oral investigations · 2022Pooled it
- The anti-fungal effect of miconazole and miconazole-loaded chitosan nanoparticles gels in diabetic patients with Oral candidiasis-randomized control clinical trial and microbiological analysis.BMC oral health · 2024Trial
- Antimicrobial photodynamic therapy in the treatment of oral erythematous candidiasis: a controlled and randomized clinical trial.Clinical oral investigations · 2023Trial
- Efficacy and Safety of Fluconazole Mucoadhesive Patches in Human Immunodeficiency Virus-Related Oral Candidiasis.Journal of the International Association of Providers of AIDS CareTrial
- Gold Nanoparticles Coated With the Antimicrobial Peptide Os-C(W5): Anticandidal and Biological Activity.Journal of peptide science : an official publication of the European Peptide Society · 2026Article
- A retrospective study comparing the severe cutaneous adverse reactions in patients receiving triazole antifungal therapy and literature analysis.Medical mycology · 2026Article
- Effects of Carvacrol on Morphogenesis and Lipase-Associated Phenotypes in Clinical Isolates ofJournal of fungi (Basel, Switzerland) · 2026Article
- Unraveling Oral Dysbiosis: Microbial Complexity in Common Oral Diseases.MicrobiologyOpen · 2026Review
- Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents.Journal of fungi (Basel, Switzerland) · 2026Review
- Clinical and Microbiological Profile of Oral Candidiasis: A Retrospective Study.Pathogens (Basel, Switzerland) · 2026Article
- Research and Application of the Polyene Macrolide Antibiotic Nystatin.Molecules (Basel, Switzerland) · 2026Review
- Metabolomic profiling reveals alterations in Candida pathophysiology and host interactions during primary oral candidiasis and following antifungal treatment.Scientific reports · 2026Article
- Prevalence and Risk Factors for Oropharyngeal, Esophageal, and Oral Candidiasis in HIV-Positive Individuals: A Systematic Review and Meta-Analysis.Interdisciplinary perspectives on infectious diseases · 2026Review
- Molecular mechanisms, pathogenesis and therapeutic advances ofFrontiers in cellular and infection microbiology · 2026Review
- Cytotoxicity and antifungal effects of combined dexamethasone and miconazole on human oral keratinocytes, gingival fibroblasts, and Candida albicans.Odontology · 2026Article
- Antifungal Effects of Pterostilbene onJournal of fungi (Basel, Switzerland) · 2025Article
- Antifungal treatment strategies and their impact on resistance development in clinical settings.The Journal of antimicrobial chemotherapy · 2025Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandidiasis is one of the most common opportunistic oral infections that presents different acute and chronic clinical presentations with diverse diagnostic and therapeutic approaches. The present study carries out a bibliographic review on the therapeutic tools available against oral candidiasis and their usefulness in each clinical situation. MATERIAL AND
methodsRecent studies on treatment of oral candidiasis were retrieved from PubMed and Cochrane Library.
resultsNystatin and miconazole are the most commonly used topical antifungal drugs. Both antifungal drugs are very effective but need a long time of use to eradicate the infection. The pharmacological presentations of miconazole are more comfortable for patients but this drug may interact with other drugs and this fact should be assessed before use. Other topical alternatives for oral candidiasis, such as amphotericin B or clotrimazole, are not available in many countries. Oral fluconazole is effective in treating oral candidiasis that does not respond to topical treatment. Other systemic treatment alternatives, oral or intravenous, less used are itraconazole, voriconazole or posaconazole. Available novelties include echinocandins (anidulafungin, caspofungin) and isavuconazole. Echinocandins can only be used intravenously. Isavuconazole is available for oral and intravenous use. Other hopeful alternatives are new drugs, such as ibrexafungerp, or the use of antibodies, cytokines and antimicrobial peptides.
conclusionsNystatin, miconazole, and fluconazole are very effective for treating oral candidiasis. There are systemic alternatives for treating recalcitrant infections, such as the new triazoles, echinocandins, or lipidic presentations of amphotericin B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.